Young Paris based company pioneering enzymatic DNA synthesis. Sector: Healthcare. Country: France. Fund: LSP 6 Entry 2019. Axtarish: dnascript.com.

DNA Script today announced an oversubscribed Series B fundraising of $38.5M led by LSP, one of Europe's largest and most experienced healthcare investment ...

DNA Script Closes $200 Million Series C Financing with world-class investors, including T. Rowe Price, Baillie Gifford, and Fidelity.

DNA Script was created to revolutionize access to synthetic DNA. The technology that the company has developed allows for a rapid, convenient way to access DNA ...

EQT Life Sciences EQT Life Science develops novel medications, devices, and ... DNA Script picks up $38.5 million to make DNA production faster and simpler.

DNA Script, transforming how molecular biology translates to human health, personalized medicine, and synthetic biology. Here you'll find information about ...

17 окт. 2024 г. · DNA Script, a leader in enzymatic DNA synthesis, today announced the appointment of Marc Montserrat as its new Chief Executive Officer.

Proceeds from this financing will be used to advance the SYNTAX Platform, DNA Script's first commercial product powered by its proprietary EDS technology. ... EQT ...

29 июл. 2020 г. · PARIS and SOUTH SAN FRANCISCO, Calif., July 29, 2020—DNA Script today announced a $50 million extension to its Series B financing, bringing the ...

DNA Script is a leading company in manufacturing de novo synthetic nucleic acids using enzymatic DNA synthesis (EDS) technology.